An Introduction to Multiple Myeloma
Despite numerous advances in the last decade, multiple myeloma remains an incurable disease, characterised by relapses that ultimately result in uncontrolled disease and death. However, novel agents, such as proteasome inhibitors, immunomodulatory drugs and CD38-directed monoclonal antibodies, have substantially improved survival and tolerability. These emerging agents include immune checkpoint inhibitors and chimeric antigen receptor-engineered T-cell therapies, although eventual relapse remains an issue.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Our supporting partners do not constitute an endorsement of the content on this page.
Multiple Myeloma Content
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma
touchREVIEWS in Oncology & Haematology. 2021;17(1):Online ahead of journal publication
Multiple myeloma is a plasma cell malignancy that typically develops in individuals in their late 60s with an average survival time of ~8 years.1 Despite recent advances in treatment, multiple myeloma remains largely incurable due to development of drug resistance in tumour cells. Patients often relapse even after autologous stem cell transplant and multiple lines […]
Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021
Watch this two-part activity exploring recent data for BCMA-targeting agents in multiple myeloma. Filmed following the European Hematology Association 2021 Virtual Congress. Part 1: Watch multiple myeloma expert Dr María-Victoria Mateos review key data from the EHA2021 Virtual Congress Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview
- Recall efficacy data for BCMA-targeting agents in the treatment of multiple myeloma
- Describe the safety data for BCMA-targeting agents in the treatment of multiple myeloma
- Discuss how the latest data on BCMA-targeting agents may affect the management of patients with multiple myeloma
Integrating BCMA-targeting agents into the treatment pathway for relapsed/refractory multiple myeloma
Watch a panel of experts discuss the use of BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma.
- Discuss the potential of BCMA-targeting agents to improve outcomes for patients with relapsed/refractory multiple myeloma
- Identify patients with relapsed/refractory multiple myeloma who may benefit from treatment with a BCMA-targeting agent
- Use strategies to monitor for and manage the adverse events associated with BCMA-targeting agents
Improving outcomes in multiple myeloma with new treatment targets
Watch a panel of experts discuss how novel targeted therapies are changing the treatment paradigm for multiple myeloma to achieve the best outcomes for patients.
- Recall the mechanisms of action and data for relapsed/refractory multiple myeloma treatments with novel agents
- Discuss the adverse event (AE) profiles of treatments with novel targets and how AEs could be managed in clinical practice
- Describe the possible role of agents with novel targets earlier in the multiple myeloma treatment pathway
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Latest Developments in Cellular Therapy for Multiple Myeloma
Oncology & Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111
Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable […]
Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial
We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) […]
Precision medicine in RRMM: Understanding how the data can be applied to practice
Watch a panel of experts discuss the latest advances in the treatment of relapsed and/or refractory multiple myeloma and the potential for precision medicine.
- Describe the current challenges in the treatment of multiple myeloma and considerations for overcoming poor prognosis
- Discuss the efficacy and safety data of novel agents being investigated in patients with RRMM
- Describe approaches to selecting treatment for patients with RRMM and the potential for precision medicine
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!